F-star Appoints Darlene Deptula-Hicks as Chief Financial Officer and Opens Office in Cambridge, MA

• Darlene Deptula-Hicks appointed new Chief Financial Officer
• Tolga Hassan appointed Chief Operating Officer
• Lindsey Trickett appointed VP, Investor Relations and Communications
• US office established in Cambridge, MA. to drive company’s growth

CAMBRIDGE, England & CAMBRIDGE, Mass.–(BUSINESS WIRE)–F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company
delivering tetravalent bispecific antibodies for a paradigm-shift in
cancer therapy, today announces the appointment of Darlene
Deptula-Hicks, MBA as Chief Financial Officer (CFO), succeeding Tolga
Hassan, who is appointed to serve as F-star’s Chief Operating Officer.

Darlene Deptula-Hicks joins F-star from Northern Biologics, Inc., a
clinical-stage biotechnology company focused on discovering and
developing first-in-class antibody therapeutics in oncology. Previously,
Darlene held CFO positions across both private and publicly listed US
companies, including Pieris Pharmaceuticals Inc., Microline Surgical
Inc. and T2 Biosystems Inc. She brings to F-star a proven track record
of finance strategy and leadership, capital raising, industry knowledge
and the ability to build strong strategic partnerships.

Darlene Deptula-Hicks, CFO of F-star, said: “It is a very
exciting time to be joining F-star given its evolution to a
fully-fledged clinical-stage, international business. The company’s
pipeline of promising bispecific antibodies has the potential to address
the growing need for, and commercial opportunity from, more efficacious
therapies for cancer patients. I am excited to join the
management team of this next-generation immunotherapy business.”

Eliot Forster, CEO of F-star, said: “We believe Darlene’s
strong commercial and capital markets experience from within the life
sciences sector will play a critical role in our transition and I’m
delighted that she has joined the company. Tolga’s expertise and company
knowledge continues to be vital to our success as we work towards
realising our ambition to bring new drugs to cancer patients as quickly
as we can.”

To support F-star’s international expansion strategy, the company has
also established US operations based in Cambridge, MA. Research
operations will continue at the company’s site in Cambridge, UK, while
the US office will support the growth of F-star’s in-house financial,
clinical and regulatory activities.

F-star has also appointed Lindsey Trickett as Vice President of Investor
Relations and Communications. Lindsey brings with her a wealth of
experience in investor relations and antibody drug development. She
joins F-star from Intellia Therapeutics, Inc., where she served as a
Vice President of Investor Relations. Previously, Lindsey held senior IR
and strategic marketing positions at AstraZeneca plc and spent over a
decade in roles of increasing responsibility at MedImmune,
LLC/AstraZeneca plc.

Both Darlene and Lindsey will be based out of F-star’s US office.

– ENDS –

About F-star Therapeutics Ltd

F-star is a leading clinical-stage biopharmaceutical company delivering
tetravalent bispecific antibodies for a paradigm-shift in cancer
therapy. By developing medicines that seek to block tumour immune
evasion, the Company’s goal is to offer patients greater and more
durable benefits than current immuno-oncology treatments. Through its
proprietary tetravalent, bispecific antibody (mAb²™) format, F-star is
generating first- and best-in-class drug candidates with monoclonal
antibody-like manufacturability. Building on the combined expertise of
its world-class management team and scientific leadership, F-star is
poised to deliver the next breakthrough immunotherapies for cancer
patients.

Contacts

For investor enquiries:
Lindsey Trickett
VP
Investor Relations & Communications
+1 240 543 7970
[email protected]

Consilium
Strategic Communications
Chris Gardner, Sue Stuart, David Daley
Tel:
+44 (0)20 3709 5700
E-mail: [email protected]

For
media enquiries
Pierre Peotta
Communications Manager
+44
(0)1223 948 094
+44 (0)7392 080 279
[email protected]

US
Catherine
London, US President
Tel: +1 917-763-2709
E-mail: [email protected]